Mangangot, Mark Caleb R.
HRN: 24-14-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/15/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/15/2025
01/22/2025
IV
650 Mg
Q8
AGE; PCAP
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes